Eid ul Adha Mubarak - from Asrar Qureshi

Eid ul Adha Mubarak - from Asrar Qureshi

Dear Readers! Please accept my heartfelt wishes and prayers on the occasion of Eid ul Adha 2024


The whole world is in turmoil. Injustice, Cruelty, Crimes against Humanity, Oppression, Suppression of Freedom, Might is Ultra Right, are order of the day. No one is willing to side with the weak, the poor, and the oppressed. Everything from social values to religion are up for sale to make quick money.

We, meanwhile, celebrate Eid with 'traditional fervour'. We worry only about what should be cooked today and in the next few days.

Allah Knows if our animal sacrifices are enough to expiate us from our sins. Allah Knows if we carry the real spirit of sacrifice. Let us take a moment to think.

Comments

Post a Comment

Popular posts from this blog

Cannabis Based Drugs (CBDs) and A Brief History of Use of Cannabis sativa Part I – Blog Post by Asrar Qureshi

Image
Dear Colleagues!  Today is Pharma Veterans Blog Post #150. Pharma Veterans shares your wealth of knowledge and wisdom with others for the benefit of entire Pharma Community. It aims to recognize and celebrate the Pharma Industry Professionals.  Pharma Veterans Blog  is published by Asrar Qureshi on WordPress , the top blog site. If you wish to share your stories, ideas and thoughts, please email to asrar@asrarqureshi.com for publishing your contributions here . During 2018, US FDA approved three drugs derived from Cannabis. It is a significant and interesting development, from an illegal substance to approved medication. Through this series, I shall take you through the history of Cannabis and how it reached where it is today. Prior to this, medical use of cannabis had seen steady rise in the last ten years. The reasons included stronger movement together legalization of Cannabis and growing body of evidence on its benefits in certain medical conditions. This may be just the
Read more

New Year 2024– Ideas For A Life Worth Living – Asrar Qureshi’s Blog Post #894

Image
New Year –Ideas For A Life Worth Living – Asrar Qureshi’s Blog Post #894 Dear Colleagues!  This is Asrar Qureshi’s Blog Post #894 for Pharma Veterans. Pharma Veterans  aims to share knowledge and wisdom from Veterans for the benefit of Community at large. Pharma Veterans Blog is published by Asrar Qureshi on  WordPress, the top blog site. Please email to asrar@asrarqureshi.com for publishing your contributions here. Credit: Anna Tarazevich Credit: Sami Anas Welcome New Year – 2024. Let Us Pray that the New Year Brings Peace, Comfort, Calm, Opportunities, Justice, Fair play, Fulfilment, and Makes Life Worth Living for Us. Aameen.  I have been a longtime admirer of Maria Popova who fled from Hungary (I guess) and came to the US at a very young age. She is deep into many literary pursuits and has been publishing a Newsletter which was previously named ‘Brainpickings’ and now renamed as ‘The Marginalian’. She does enormous amount of work to keep this newsletter and other projects going. Re
Read more

Two Landmark New Drug Approvals – Asrar Qureshi’s Blog Post #897

Image
Two Landmark New Drug Approvals – Asrar Qureshi’s Blog Post #897 Dear Colleagues!  This is Asrar Qureshi’s Blog Post #897 for Pharma Veterans. Pharma Veterans  aims to share knowledge and wisdom from Veterans for the benefit of Community at large. Pharma Veterans Blog is published by Asrar Qureshi on  WordPress, the top blog site. Please email to asrar@asrarqureshi.com for publishing your contributions here. Credit: Google Images Credit: Google Images Credit: Google Images In December 2023, US Food and Drug Administration approved two gene therapy-based drugs for sickle cell disease treatment.  CASGEVY (exagamglogene autotemcel) is the first approved CRISPR/Cas9 genome-edited cell therapy for the treatment of Sickle Cell Disease – SCD, in patients 12 years or older with frequent vaso-occlusive crises (VOCs). CASGEVY has been developed by Vertex Pharmaceuticals and CRISPR Therapeutics and has been shown to reduce or eliminate vaso-occlusive crises for SCD patients.  The FDA also approve
Read more